Related Experiment Video
Updated: May 8, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Acquired haemophilia A: a 2013 update
Massimo Franchini1, Pier Mannuccio Mannucci
1Pier Mannuccio Mannucci, MD, Scientific Direction, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, Via Pace 9, 20122 Milan, Italy, Tel.: +39 02 5503 5414, Fax: +39 02 54 100 125,
Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Management focuses on controlling bleeding and eradicating FVIII autoantibodies.
Area of Science:
- Hematology
- Immunology
Background:
- Acquired haemophilia A (AHA) is a rare, severe bleeding disorder.
- It results from autoantibodies targeting coagulation factor VIII (FVIII).
- AHA is more prevalent in the elderly and linked to postpartum status, malignancies, autoimmune diseases, or drug exposure; however, 50% of cases are idiopathic.
Purpose of the Study:
- To review current knowledge on AHA epidemiology, diagnosis, and clinical features.
- To focus on recent advances in managing this challenging bleeding disorder.
Main Methods:
- This is a narrative review.
- It summarizes existing literature on AHA.
Main Results:
- AHA epidemiology and risk factors are discussed.
- Diagnostic approaches are outlined.
- Current and emerging therapeutic strategies are presented.
Conclusions:
- Effective AHA management requires addressing the underlying cause, controlling acute bleeding, and eradicating FVIII autoantibodies.
- Advances in treatment offer improved outcomes for patients with AHA.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Venous Thrombosis III: Interprofessional Care
